EG26287A - A stabilized solid composition containing pregabalin and a glycol or glycerol humectant - Google Patents

A stabilized solid composition containing pregabalin and a glycol or glycerol humectant

Info

Publication number
EG26287A
EG26287A EG1999050553A EG55399A EG26287A EG 26287 A EG26287 A EG 26287A EG 1999050553 A EG1999050553 A EG 1999050553A EG 55399 A EG55399 A EG 55399A EG 26287 A EG26287 A EG 26287A
Authority
EG
Egypt
Prior art keywords
composition containing
glycol
solid composition
stabilized solid
humectant
Prior art date
Application number
EG1999050553A
Other languages
Arabic (ar)
Inventor
اكيرا اوماتسو
Original Assignee
وارنر لامبرت كومبانى
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=15097314&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EG26287(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by وارنر لامبرت كومبانى filed Critical وارنر لامبرت كومبانى
Application granted granted Critical
Publication of EG26287A publication Critical patent/EG26287A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Body Structure For Vehicles (AREA)
  • Arrangement Of Transmissions (AREA)

Abstract

1. Technical Result Increase in efficiency of neuropathologic diseases treatment. 2. Essence A pharmaceutical composition containing as an active compound 4-amino-3-substituted-butanoic acid derivative of the general formula NH2 CH2 - C - CH2 COOH R1 R2 wherein the values R1 and R2, have the values indicated in the description, humectants in pharmaceutically effective amount and pharmaceutically acceptable auxiliaries. The composition is obtained by mixing the mentioned compound, humectant and pharmaceutically acceptable auxiliaries. 3. Field of Application Medicine. Tables: 10
EG1999050553A 1998-05-15 1999-05-13 A stabilized solid composition containing pregabalin and a glycol or glycerol humectant EG26287A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP13312298A JP3761324B2 (en) 1998-05-15 1998-05-15 Passenger rice transplanter

Publications (1)

Publication Number Publication Date
EG26287A true EG26287A (en) 2013-06-12

Family

ID=15097314

Family Applications (1)

Application Number Title Priority Date Filing Date
EG1999050553A EG26287A (en) 1998-05-15 1999-05-13 A stabilized solid composition containing pregabalin and a glycol or glycerol humectant

Country Status (16)

Country Link
JP (1) JP3761324B2 (en)
CN (1) CN1171587C (en)
AT (1) ATE407668T1 (en)
CA (1) CA2325045C (en)
CY (1) CY1108488T1 (en)
DE (1) DE69939532D1 (en)
DK (1) DK1077691T3 (en)
EA (1) EA006553B1 (en)
EE (1) EE05530B1 (en)
EG (1) EG26287A (en)
ES (1) ES2312208T3 (en)
GE (1) GEP20032987B (en)
IL (2) IL139202A0 (en)
NZ (1) NZ507162A (en)
PT (1) PT1077691E (en)
UA (1) UA76398C2 (en)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4904636B2 (en) * 2001-05-29 2012-03-28 井関農機株式会社 Tractor frame
JP5047022B2 (en) * 2008-03-24 2012-10-10 ヤンマー株式会社 Upper and lower split engine storage package connection structure
WO2013008182A1 (en) * 2011-07-10 2013-01-17 Mahesh Kandula Prodrugs of gaba analogs
WO2014037832A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment of epilepsy and neurological diseases
US9399634B2 (en) 2012-05-07 2016-07-26 Cellix Bio Private Limited Compositions and methods for the treatment of depression
WO2013168019A1 (en) * 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neuropathic pain
CA2872975A1 (en) 2012-05-07 2013-11-14 Cellixbio Private Limited Compositions and methods for the treatment of neurological disorders
AU2013257742A1 (en) 2012-05-07 2014-11-27 Cellixbio Private Limited Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
US9434704B2 (en) 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
US9266823B2 (en) 2012-05-08 2016-02-23 Cellix Bio Private Limited Compositions and methods for the treatment of parkinson's disease
WO2013167991A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic disorders
WO2013167992A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of inflammatory disorders
WO2013168025A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of blood clotting disorders
US9573927B2 (en) 2012-05-10 2017-02-21 Cellix Bio Private Limited Compositions and methods for the treatment of severe pain
US9499527B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of familial amyloid polyneuropathy
US9315478B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9339484B2 (en) 2012-05-10 2016-05-17 Cellix Bio Private Limited Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
WO2013167999A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurologic diseases
US9394288B2 (en) 2012-05-10 2016-07-19 Cellix Bio Private Limited Compositions and methods for the treatment of asthma and allergy
WO2013168033A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neurologic diseases
WO2013168004A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of fibromyalgia pain
US9242939B2 (en) 2012-05-10 2016-01-26 Cellix Bio Private Limited Compositions and methods for the treatment of respiratory disorders
US20150087674A1 (en) * 2012-05-10 2015-03-26 Mahesh Kandula Compositions and methods for the treatment of severe pain
WO2013168002A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological conditions
WO2013168011A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of chronic pain
WO2013168001A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
SG11201407318UA (en) 2012-05-10 2014-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of metabolic syndrome
US9434729B2 (en) 2012-05-23 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
US9227974B2 (en) 2012-05-23 2016-01-05 Cellex Bio Private Limited Compositions and methods for the treatment of respiratory disorders
US9492409B2 (en) 2012-05-23 2016-11-15 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
JP2015518855A (en) 2012-05-23 2015-07-06 セリックスビオ プライヴェート リミテッド Compositions and methods for the treatment of mucositis
SG11201407322QA (en) 2012-05-23 2014-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of multiple sclerosis
CA2873096A1 (en) 2012-05-23 2013-11-28 Cellixbio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
US9187427B2 (en) 2012-08-03 2015-11-17 Cellix Bio Private Limited N-substituted nicotinamide compounds and compositions for the treatment migraine and neurologic diseases
US9624168B2 (en) 2012-09-06 2017-04-18 Cellix Bio Private Limited Compositions and methods for the treatment inflammation and lipid disorders
SG11201407325YA (en) 2012-09-08 2014-12-30 Cellix Bio Private Ltd Compositions and methods for treatment of inflammation and lipid disorders
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
CA2914461A1 (en) 2013-06-04 2014-12-11 Cellixbio Private Limited Compositions and methods for the treatment of diabetes and pre-diabetes
WO2016110865A1 (en) 2015-01-06 2016-07-14 Cellix Bio Private Limited Compositions and methods for the treatment of inflammation and pain
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
WO2016046835A1 (en) 2014-09-26 2016-03-31 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological disorders
CN107207403A (en) 2014-09-29 2017-09-26 塞尔利克斯生物私人有限公司 Composition and method for treating multiple sclerosis
CN104352476A (en) * 2014-10-21 2015-02-18 齐宏 Gabapentin capsule and preparation method thereof
SG11201703369WA (en) 2014-10-27 2017-05-30 Cellix Bio Private Ltd Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases

Also Published As

Publication number Publication date
ATE407668T1 (en) 2008-09-15
NZ507162A (en) 2003-11-28
EA006553B1 (en) 2006-02-24
CN1300213A (en) 2001-06-20
EA200001154A1 (en) 2001-06-25
CY1108488T1 (en) 2014-04-09
DK1077691T3 (en) 2008-10-27
UA76398C2 (en) 2006-08-15
JP3761324B2 (en) 2006-03-29
CN1171587C (en) 2004-10-20
ES2312208T3 (en) 2009-02-16
CA2325045A1 (en) 1999-11-25
JPH11318133A (en) 1999-11-24
GEP20032987B (en) 2003-06-25
IL139202A0 (en) 2001-11-25
DE69939532D1 (en) 2008-10-23
CA2325045C (en) 2005-05-03
EE05530B1 (en) 2012-04-16
PT1077691E (en) 2008-11-04
IL139202A (en) 2014-12-31
EE200000671A (en) 2002-04-15

Similar Documents

Publication Publication Date Title
EG26287A (en) A stabilized solid composition containing pregabalin and a glycol or glycerol humectant
BR9510168A (en) Polyamino acid compound composition unit dosage form and method for preparing a composition
MY119403A (en) Novel compounds with analgesic effect.
ES2173400T3 (en) COMPOSITIONS CONTAINING CINC FOR ORAL ADMINISTRATION THAT INCLUDE A COPPER COMPOUND AND AN AMINO ACID.
MY132705A (en) Novel compounds with analgesic effect
CA2239174A1 (en) Novel compounds with analgesic effect
ATE260658T1 (en) PHARMACEUTICAL PREPARATIONS FOR REDUCING RESPIRATORY DEPRESSION
GEP20022654B (en) Indazole Amide Compounds As Serotoninergic Agents
CA2108903A1 (en) Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
ATE84045T1 (en) INHIBITING SUBSTANCES ENKEPHALINASE-B THEIR PREPARATION AND THEIR PHARMACEUTICAL COMPOSITIONS.
EP0647616A4 (en) Zinc tranexamate compound.
ZA922910B (en) Heterocylic pharmaceutical compounds preparation and use
DE69531736D1 (en) MEDICINAL PRODUCT CONTAINING OXYTETRACYCLIN WITH DELAYED DELIVERY OF ACTIVE SUBSTANCE
GEP19991872B (en) Novel Taxoids, Preparations Thereof, and Pharmaceutical Compositions Containing Same
GEP20043231B (en) Resorcinol Composition
CA2263184A1 (en) Methods and compositions for increasing the anaerobic working capacity in tissues
WO1992017065A3 (en) Method of inhibiting fibrosis
ES2005042A6 (en) Anticonvulsant composition containing amino acid derivative and use of said amino acid derivative.
WO2001007029A3 (en) Substituted guanidines and the use thereof
IT1273455B (en) THIOLIC DERIVATIVES WITH METALLOPEPTIDASE INHIBITIVE ACTIVITY
AU8900498A (en) Compounds and pharmaceutical compositions thereof for eliciting analgesic effects